중추신경계(CNS) 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Central Nervous System Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1508417
리서치사:Transparency Market Research
발행일:2024년 05월
페이지 정보:영문 174 Pages
라이선스 & 가격 (부가세 별도)
한글목차
중추신경계(CNS) 치료제 시장 - 조사 범위
TMR의 중추신경계(CNS) 치료제 세계 시장 조사 보고서는 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 삼아 2018년부터 2034년까지 세계 중추신경계(CNS) 치료제 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 중추신경계(CNS) 치료제 시장의 연평균 성장률(CAGR%)도 제시합니다.
이 보고서는 1차적으로 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 인터뷰하고, 2차적으로 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 문서를 검토하여 중추신경계(CNS) 치료제 시장을 이해하고자 했습니다. 관련 문서를 참고하였습니다.
시장 현황
2023년 시장 규모
1,024억 달러
2034년 시장 규모
2,318억 달러
CAGR
7.7%
이 보고서는 세계 중추신경계(CNS) 치료제 시장의 경쟁 환경을 조사했습니다. 세계 중추신경계(CNS) 치료제 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에서 프로파일링된 세계 중추신경계(CNS) 치료제 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약
제4장 시장 개요
서론
개요
시장 역학
시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품 및 브랜드 분석
주요 M&A
COVID-19의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 약제 클래스별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 약제 클래스별, 2020-2034년
진통제
항코린제
항경련제
진정제 및 수면제
항우울제
기타(항정신병약 등)
시장의 매력 분석 : 약제 클래스별
제7장 세계 시장 분석과 예측 : 질환별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 질환별, 2020-2034년
신경 퇴행성 질환
알츠하이머병
파킨슨병
헌팅턴병
루게릭병
기타(다발성 경화증 등)
정신건강
불안 장애
간질
정신병성 장애
기타(기분 장애 등)
신경혈관 질환
중추신경계 외상
중추신경계 암
기타(감염증등)
시장의 매력 분석 : 질환별
제8장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 유통 채널별, 2020-2034년
병원 약국
소매 약국
온라인 약국
시장의 매력 분석 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 분석 : 지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 예측
제14장 중동 및 아프리카 시장 분석과 예측
제15장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Biogen
Otsuka Pharmaceutical Co., Ltd.
Eli Lilly and Company
Merck & Co. Inc.
AstraZeneca
Novartis AG
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Takeda Pharmaceuticals
Johnson & Johnson Services, Inc.
LSH
영문 목차
영문목차
Central Nervous System (CNS) Therapeutics Market - Scope of Report
TMR's report on the global central nervous system (CNS) therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global central nervous system (CNS) therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global central nervous system (CNS) therapeutics market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the central nervous system (CNS) therapeutics market.
Market Snapshot
Market Value in 2023
US$ 102.4 Bn
Market Value in 2034
US$ 231.8 Bn
CAGR
7.7%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global central nervous system (CNS) therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global central nervous system (CNS) therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global central nervous system (CNS) therapeutics market.
The report delves into the competitive landscape of the global central nervous system (CNS) therapeutics market. Key players operating in the global central nervous system (CNS) therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global central nervous system (CNS) therapeutics market profiled in this report.
Key Questions Answered in Global central nervous system (CNS) therapeutics Market Report:
What is the sales/revenue generated by central nervous system (CNS) therapeutics across all regions during the forecast period?
What are the opportunities in the global central nervous system (CNS) therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Central Nervous System (CNS) Therapeutics Market - Research Objectives and Research Approach
The comprehensive report on the global central nervous system (CNS) therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global central nervous system (CNS) therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global central nervous system (CNS) therapeutics market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Central Nervous System (CNS) Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Analgesics
6.3.2. Anti-Cholinergic Agents
6.3.3. Anticonvulsants
6.3.4. Sedatives and Hypnotics
6.3.5. Anti-Depressants
6.3.6. Others (Antipsychotics, etc.)
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Type, 2020-2034
7.3.1. Neurodegenerative Disorders
7.3.1.1. Alzheimer's Disease
7.3.1.2. Parkinson's Disease
7.3.1.3. Huntington's Disease
7.3.1.4. Amyotrophic Lateral Sclerosis
7.3.1.5. Others (Multiple Sclerosis, etc.)
7.3.2. Mental Health
7.3.2.1. Anxiety Disorders
7.3.2.2. Epilepsy
7.3.2.3. Psychotic Disorders
7.3.2.4. Others (Mood Disorders, etc.)
7.3.3. Neurovascular Diseases
7.3.4. CNS Trauma
7.3.5. CNS Cancer
7.3.6. Others (Infectious Disorders, etc.)
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034.
10.3.1. Analgesics
10.3.2. Anti-Cholinergic Agents
10.3.3. Anticonvulsants
10.3.4. Sedatives and Hypnotics
10.3.5. Anti-Depressants
10.3.6. Others (Antipsychotics, etc.)
10.4. Market Value Forecast, by Disease Type, 2020-2034.
10.4.1. Neurodegenerative Disorders
10.4.1.1. Alzheimer's Disease
10.4.1.2. Parkinson's Disease
10.4.1.3. Huntington's Disease
10.4.1.4. Amyotrophic Lateral Sclerosis
10.4.1.5. Others (Multiple Sclerosis, etc.)
10.4.2. Mental Health
10.4.2.1. Anxiety Disorders
10.4.2.2. Epilepsy
10.4.2.3. Psychotic Disorders
10.4.2.4. Others (Mood Disorders, etc.)
10.4.3. Neurovascular Diseases
10.4.4. CNS Trauma
10.4.5. CNS Cancer
10.4.6. Others (Infectious Disorders, etc.)
10.5. Market Value Forecast, by Distribution Channel, 2020-2034.
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Disease Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
11.3.1. Analgesics
11.3.2. Anti-Cholinergic Agents
11.3.3. Anticonvulsants
11.3.4. Sedatives and Hypnotics
11.3.5. Anti-Depressants
11.3.6. Others (Antipsychotics, etc.)
11.4. Market Value Forecast, by Disease Type, 2020-2034.
11.4.1. Neurodegenerative Disorders
11.4.1.1. Alzheimer's Disease
11.4.1.2. Parkinson's Disease
11.4.1.3. Huntington's Disease
11.4.1.4. Amyotrophic Lateral Sclerosis
11.4.1.5. Others (Multiple Sclerosis, etc.)
11.4.2. Mental Health
11.4.2.1. Anxiety Disorders
11.4.2.2. Epilepsy
11.4.2.3. Psychotic Disorders
11.4.2.4. Others (Mood Disorders, etc.)
11.4.3. Neurovascular Diseases
11.4.4. CNS Trauma
11.4.5. CNS Cancer
11.4.6. Others (Infectious Disorders, etc.)
11.5. Market Value Forecast, by Distribution Channel, 2020-2034.
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Distribution Channel, 2020-2034.
11.6.1. Hospitals
11.6.2. Biopharmaceutical Companies
11.6.3. Research Organizations and Academic Institutes
11.7. Market Value Forecast, by Country/Sub-region, 2020-2034
11.7.1. Germany
11.7.2. U.K.
11.7.3. France
11.7.4. Italy
11.7.5. Spain
11.7.6. Rest of Europe
11.8. Market Attractiveness Analysis
11.8.1. By Drug Class
11.8.2. By Disease Type
11.8.3. By Distribution Channel
11.8.4. By Country/Sub-region
12. Asia Pacific Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034.
12.3.1. Analgesics
12.3.2. Anti-Cholinergic Agents
12.3.3. Anticonvulsants
12.3.4. Sedatives and Hypnotics
12.3.5. Anti-Depressants
12.3.6. Others (Antipsychotics, etc.)
12.4. Market Value Forecast, by Disease Type, 2020-2034.
12.4.1. Neurodegenerative Disorders
12.4.1.1. Alzheimer's Disease
12.4.1.2. Parkinson's Disease
12.4.1.3. Huntington's Disease
12.4.1.4. Amyotrophic Lateral Sclerosis
12.4.1.5. Others (Multiple Sclerosis, etc.)
12.4.2. Mental Health
12.4.2.1. Anxiety Disorders
12.4.2.2. Epilepsy
12.4.2.3. Psychotic Disorders
12.4.2.4. Others (Mood Disorders, etc.)
12.4.3. Neurovascular Diseases
12.4.4. CNS Trauma
12.4.5. CNS Cancer
12.4.6. Others (Infectious Disorders, etc.)
12.5. Market Value Forecast, by Distribution Channel, 2020-2034.
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Distribution Channel, 2020-2034.
12.6.1. Hospitals
12.6.2. Biopharmaceutical Companies
12.6.3. Research Organizations and Academic Institutes
12.7. Market Value Forecast, by Country/Sub-region, 2020-2034
12.7.1. China
12.7.2. Japan
12.7.3. India
12.7.4. Australia & New Zealand
12.7.5. Rest of Asia Pacific
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Disease Type
12.8.3. By Distribution Channel
12.8.4. By Country/Sub-region
13. Latin America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
13.3.1. Analgesics
13.3.2. Anti-Cholinergic Agents
13.3.3. Anticonvulsants
13.3.4. Sedatives and Hypnotics
13.3.5. Anti-Depressants
13.3.6. Others (Antipsychotics, etc.)
13.4. Market Value Forecast, by Disease Type, 2020-2034.
13.4.1. Neurodegenerative Disorders
13.4.1.1. Alzheimer's Disease
13.4.1.2. Parkinson's Disease
13.4.1.3. Huntington's Disease
13.4.1.4. Amyotrophic Lateral Sclerosis
13.4.1.5. Others (Multiple Sclerosis, etc.)
13.4.2. Mental Health
13.4.2.1. Anxiety Disorders
13.4.2.2. Epilepsy
13.4.2.3. Psychotic Disorders
13.4.2.4. Others (Mood Disorders, etc.)
13.4.3. Neurovascular Diseases
13.4.4. CNS Trauma
13.4.5. CNS Cancer
13.4.6. Others (Infectious Disorders, etc.)
13.5. Market Value Forecast, by Distribution Channel, 2020-2034.
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Distribution Channel, 2020-2034.
13.6.1. Hospitals
13.6.2. Biopharmaceutical Companies
13.6.3. Research Organizations and Academic Institutes
13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
13.7.1. Brazil
13.7.2. Mexico
13.7.3. Rest of Latin America
13.8. Market Attractiveness Analysis
13.8.1. By Drug Class
13.8.2. By Disease Type
13.8.3. By Distribution Channel
13.8.4. By Country/Sub-region
14. Middle East & Africa Central Nervous System (CNS) Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2020-2034
14.3.1. Analgesics
14.3.2. Anti-Cholinergic Agents
14.3.3. Anticonvulsants
14.3.4. Sedatives and Hypnotics
14.3.5. Anti-Depressants
14.3.6. Others (Antipsychotics, etc.)
14.4. Market Value Forecast, by Disease Type, 2020-2034.
14.4.1. Neurodegenerative Disorders
14.4.1.1. Alzheimer's Disease
14.4.1.2. Parkinson's Disease
14.4.1.3. Huntington's Disease
14.4.1.4. Amyotrophic Lateral Sclerosis
14.4.1.5. Others (Multiple Sclerosis, etc.)
14.4.2. Mental Health
14.4.2.1. Anxiety Disorders
14.4.2.2. Epilepsy
14.4.2.3. Psychotic Disorders
14.4.2.4. Others (Mood Disorders, etc.)
14.4.3. Neurovascular Diseases
14.4.4. CNS Trauma
14.4.5. CNS Cancer
14.4.6. Others (Infectious Disorders, etc.)
14.5. Market Value Forecast, by Distribution Channel, 2020-2034.
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Distribution Channel, 2020-2034.
14.6.1. Hospitals
14.6.2. Biopharmaceutical Companies
14.6.3. Research Organizations and Academic Institutes
14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
14.7.1. GCC Countries
14.7.2. South Africa
14.7.3. Rest of Middle East & Africa
14.8. Market Attractiveness Analysis
14.8.1. By Drug Class
14.8.2. By Disease Type
14.8.3. By Distribution Channel
14.8.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
